- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
March 26, 2024Ronald Schutz, Brendan Johnson Named to Forbes Top 200 Lawyers in the United States
-
March 21, 2024Robins Kaplan Firm Members Appointed to Law360 Editorial Boards
-
March 20, 2024Brandon Vaughn Inducted into The International Society of Barristers
-
April 5, 2024Mass Torts Made Perfect
-
April 17, 2024American Antitrust Institute Virtual CLE Lunch & Learn
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
March 2024Do We Have to Share That Information? Attorney-Client Privilege in the Multi-Entity Context
-
March 2024Sellers of a Business: Know Thyself.
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
New ANDA Cases
Winter 2012
Case Name |
Date Filed |
Judge |
Drug |
Patent No(s). |
Avanir Pharma., Inc. v. Impax Labs., Inc., 12-1298 (D. Del.) |
Oct. 8, 2012 |
Hon. Leonard P. Stark |
Nuedexta®(dextromethorphan hydrobromide / quinidine sulfate capsules) |
8,227,484 |
Purdue Pharma L.P. v. Sandoz Inc., 12-7582 (S.D.N.Y.) |
Oct. 10, 2012 |
Hon. Sidney H. Stein |
OxyContin®(oxycodone hydrochloride extended-release tablets) |
8,114,383 |
Gilead Sciences, Inc. v. Lupin Ltd., 12-7910 (S.D.N.Y.) |
Oct. 24, 2012 |
Hon. Richard J. Sullivan |
Viread®(tenofovir disoproxil fumarate tablets) |
5,922,695 5,935,946 5,977,089 6,043,230 |
Purdue Pharma. Products L.P. v. Par Pharma., Inc., 12-6738 (D.N.J.) |
Oct. 25, 2012 |
Hon. Jose L. Linares |
Intermezzo®(zolpidem tartrate sublingual tablets) |
8,242,131 8,252,809 |
Purdue Pharma. Products L.P. v. Par Formulations Private Ltd., 12-6741 (D.N.J.) |
Oct. 25, 2012 |
Hon. Jose L. Linares |
Intermezzo®(zolpidem tartrate sublingual tablets) |
8,242,131 8,252,809 |
Mallinckrodt Inc. v. Watson Labs., Inc.-Florda, 12-6744 (D.N.J.) |
Oct. 25, 2012 |
Hon. William J. Martini |
Exalgo®(hydromorphone hydrochloride extended-release tablets) |
5,914,131 |
Jazz Pharma., Inc. v. Roxane Labs., Inc., 12-6761 (D.N.J.) |
Oct. 26, 2012 |
Hon. Esther Salas |
Xyrem®(sodium oxybate oral solution) |
8,263,650 |
Acura Pharma., Inc. v. Impax Labs., Inc., 12-1371 (D. Del.) |
Oct. 31, 2012 |
Hon. Richard G. Andrews |
Oxecta®(oxycodone hydrochloride tablets) |
7,510,726 |
Acura Pharma., Inc. v. Par Pharma., Inc., 12-1372 (D. Del.) |
Oct. 31, 2012 |
Hon. Richard G. Andrews |
Oxecta®(oxycodone hydrochloride tablets) |
7,510,726 |
Acura Pharma., Inc. v. Sandoz Inc., 12-1373 (D. Del.) |
Oct. 31, 2012 |
Hon. Richard G. Andrews |
Oxecta®(oxycodone hydrochloride tablets) |
7,510,726 |
Acura Pharma., Inc. v. Watson Labs., Inc.-Florda, 12-1374 (D. Del.) |
Oct. 31, 2012 |
Hon. Richard G. Andrews |
Oxecta®(oxycodone hydrochloride tablets) |
7,510,726 |
Acura Pharma., Inc. v. Sandoz, Inc., 12-6784 (S.D.N.Y.) |
Nov. 1, 2012 |
Hon. Michael A. Shipp |
Oxecta®(oxycodone hydrochloride tablets) |
7,510,726 |
AstraZeneca Pharma. LP v. Lupin Ltd., 12-6888 (D.N.J.) |
Nov. 5, 2012 |
Hon. Joel A. Pisano |
Seroquel XR®(quetiapine fumarate extended-release tablets) |
5,948,437 |
Endo Pharma. Inc. v. Teva Pharma. USA, Inc., 12-8060 (S.D.N.Y.) |
Nov. 5, 2012 |
Hon. George B. Daniels |
Opana®ER (oxymorphone hydrochloride extended-release tablets) |
7,851,482 8,075,872 8,114,383 8,192,722 8,309,060 8,309,122 |
Endo Pharma. Inc. v. Amneal Pharma., LLC, 12-8115 (S.D.N.Y.) |
Nov. 7, 2012 |
Hon. Andrew L. Carter, Jr. |
Opana®ER (oxymorphone hydrochloride extended-release tablets) |
7,851,482 8,075,872 8,114,383 8,192,722 8,309,060 8,309,122 |
AbbVie Inc. v. Watson Pharma., Inc., 12-1409 (D. Del.) |
Nov. 8, 2012 |
Hon. Sue L. Robinson |
Niaspan®(niacin extended-release tablets) |
6,080,428 6,469,035 |
Merck Sharp & Dohme Corp. v. APP Pharma., Inc., 12-1410 (D. Del.) |
Nov. 9, 2012 |
Hon. Richard G. Andrews |
Integrilin®(eptifibatide injection) |
5,807,825 5,747,447 5,968,902 |
Ferring B.V. v. Watson Pharma., Inc., 12-1935 (D. Nev.) |
Nov. 9, 2012 |
Hon. Miranda M. Du |
Lysteda®(tranexamic acid tablets) |
8,273,795 |
Ferring B.V. v. Apotex Inc., 12-1941 (D. Nev.) |
Nov. 9, 2012 |
Hon. Gloria M. Navarro |
Lysteda®(tranexamic acid tablets) |
8,273,795 |
Endo Pharma. Inc. v. Impax Labs., Inc., 12-8317 (S.D.N.Y.) |
Nov. 14, 2012 |
Hon. P. Kevin Castel |
Opana®ER (oxymorphone hydrochloride extended-release tablets) |
7,851,482 8,075,872 8,114,383 8,192,722 8,309,060 8,309,122 |
Endo Pharma. Inc. v. Sandoz, Inc., 12-8318 (S.D.N.Y.) |
Nov. 14, 2012 |
JudgeP. Kevin Castel |
Opana®ER (oxymorphone hydrochloride extended-release tablets) |
7,851,482 8,075,872 8,114,383 8,192,722 8,309,060 8,309,122 |
Astellas US LLC v. Akorn, Inc., 12-1489 (D. Del.) |
Nov. 19, 2012 |
Hon. Sue L. Robinson |
Adenoscan®(adenosine injection) |
5,731,296 |
Millenium Pharma., Inc. v. Accord Healthcare, Inc., 12-1490 (D. Del.) |
Nov. 19, 2012 |
Hon. Gregory M. Sleet |
Velcade®(bortezomib injection) |
6,713,446 6,958,319 |
Apotex, Inc. v. Daiichi Sankyo, Inc., 12-9295 (N.D. Ill.) |
Nov. 20, 2012 |
Hon. Sharon Johnson Coleman |
Benicar®(olmesartan medoxomil tablets) |
6,878,703 |
Bayer Pharma AG v. Lupin Ltd., 12-1592 (D. Del.) |
Nov. 28, 2012 |
Hon. Christopher J. Burke |
Natazia®(estradiol valerate / dinogest tablets) |
8,071,577 |
Takeda Pharma. Co., Ltd. v. Lupin Ltd., 12-7333 (D.N.J.) |
Nov. 29, 2012 |
Hon. Joel A. Pisano |
Prevacid®SoluTab™ (lansoprazole delayed-release orally disintegrating tablets) |
6,328,994 7,431,942 7,399,485 7,875,292 |
Bayer Pharma AG v. Lupin Ltd., 12-3526 (D. Md.) |
Nov. 29, 2012 |
Hon. William D. Quarles, Jr. |
Natazia®(estradiol valerate / dinogest tablets) |
8,071,577 |
Medicis Pharma. Corp. v. Alkem Labs. Ltd., 12-1663 (D. Del.) |
Dec. 5, 2012 |
Hon. Leonard P. Stark |
Solodyn®(minocycline hydrochloride extended-release tablets) |
5,908,838 7,790,705 8,268,804 |
Medicis Pharma. Corp. v. Sidmak Labs. (Indai) Pvt. Ltd., 12-1664 (D. Del.) |
Dec. 5, 2012 |
Hon. Leonard P. Stark |
Solodyn®(minocycline hydrochloride extended-release tablets) |
5,908,838 7,790,705 8,268,804 |
Jazz Pharma., Inc. v. Roxane Labs., Inc., 12-7459 (D.N.J.) |
Dec. 5, 2012 |
Hon. Esther Salas |
Xyrem®(sodium oxybate oral solution) |
8,324,275 |
Glycobiosciences, Inc. v. Anika Therapeutics, Inc., 12-1963 (D.D.C.) |
Dec. 6, 2012 |
Hon. Rosemary M. Collyer |
Hyalofill®(hyaluronic acid ester) |
6,120,804 6,723,345 |
Medicis Pharma. Corp. v. Alkem Labs. Ltd., 12-7493 (D.N.J.) |
Dec. 6, 2012 |
Hon. Michael A. Shipp |
Solodyn®(minocycline hydrochloride extended-release tablets) |
5,908,838 7,790,705 8,268,804 |
Osi Pharma., LLC v. Roxane Labs., Inc., 12-1669 (D. Del.) |
Dec. 7, 2012 |
Hon. Sue L. Robinson |
Tarceva®(erlotinib hydrochloride tablets) |
RE41,065 6,900,221 7,087,613 |
Alkermes Pharma Ireland Ltd. v. Mylan Pharma. Inc., 12-1673 (D. Del.) |
Dec. 7, 2012 |
Hon. Sue L. Robinson |
Focalin®XR (dexmethylphenidate hydrochloride extended-release capsules) |
6,228,398 6,730,325 |
Celgene Corp. v. Mylan Pharma. Inc., 12-7590 (D.N.J.) |
Dec. 7, 2012 |
Hon. Susan D. Wigenton |
Focalin XR®(dexmethylphenidate hydrochloride extended-release capsules) |
5,908,850 6,355,656 6,528,530 5,837,284 6,635,284 7,431,944 |
Endo Pharma. Inc. v. Actavis Inc., 12-8985 (S.D.N.Y.) |
Dec. 11, 2012 |
JudgeThomas P. Griesa |
Opana®ER (oxymorphone hydrochloride extended-release tablets) |
7,851,482 8,309,122 8,329,216 |
Astellas US LLC v. Fresenius Kabi USA, LLC, 12-1699 (D. Del.) |
Dec. 12, 2012 |
Hon. Sue L. Robinson |
Adenoscan®(adenosine injection) |
5,731,296 |
Merz Pharma., LLC v. Par Pharma., Inc., 12-1723 (D. Del.) |
Dec. 17, 2012 |
Hon. Sue L. Robinson |
Cuvposa®(glycopyrrolate oral solution) |
7,638,552 7,816,396 |
Bayer Pharma AG v. Watson Pharma., Inc., 12-1726 (D. Del.) |
Dec. 18, 2012 |
Hon. Christopher J. Burke |
Natazia®(estradiol valerate / dinogest tablets) |
8,071,577 |
Endo Pharma. Inc. v. Par Pharma. Cos., Inc., 12-9261 (S.D.N.Y.) |
Dec. 19, 2012 |
JudgeThomas P. Griesa |
Opana®ER (oxymorphone hydrochloride extended-release tablets) |
7,851,482 8,309,122 8,329,216 8,075,872 8,114,383 8,192,722 8,309,060 |
Millenium Pharma., Inc. v. Actavis, Inc., 12-1750 (D. Del.) |
Dec. 21, 2012 |
Hon. Gregory M. Sleet |
Velcade®(bortezomib injection) |
6,713,446 6,958,319 |
UCB, Inc. v. Teva Pharma. USA, Inc., 12-4420 (N.D. Ga.) |
Dec. 21, 2012 |
Hon. Charles A. Pannell, Jr. |
Metadate CD®(methylphenidate hydrochloride capsules) |
6,344,215 |
Bristol-Myers Squibb Co. v. Dr. Reddy’s Labs., Ltd., 12-7800 (D.N.J.) |
Dec. 21, 2012 |
Hon. Michael A. Shipp |
Ixempra®Kit (ixabepilone for injection) |
6,670,384 7,022,330 RE41,393 |
Shionogi & Co., Ltd. v. Sandoz Inc., 12-7907 (D.N.J.) |
Dec. 28, 2012 |
Hon. Freda L. Wolfson |
Doribax®(doripenem for injection) |
8,247,402 |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.